BCL2 and Ki 67 expression in endometrial hyperplastic disorders
An observational study in a tertiary care center
Abstract
INTRODUCTION:
The pattern of expression in hyperplastic and premalignant states of endometrium helps us to study the progression of these conditions to frank malignancy. The diagnosis of endometrial hyperplasia with/without atypia is a subjective diagnosis which can affect the treatment line of the patient. This study is done to test the IHC markers BCL-2 and Ki67 on hyperplastic and malignant lesions as an attempt to make the diagnosis of type of hyperplasia more accurate.
PURPOSE:
The present study attempts to determine the relationship between proliferation and the inhibition of apoptosis in endometrial hyperplastic disorders, using monoclonal antibodies against the proliferation marker, Ki-67 and the anti-apoptotic protein, Bcl-2.
MATERIALS AND METHODS:
Histopathological test requisition forms and paraffin blocks of endometrial biopsy and endometrial curettage reported as endometrial hyperplasia or endometrial carcinoma from February 2022 to May 2023 in the Department of Pathology, Bharati medical College and Research Center, Pune.were collected. The H & E sections and IHC – BCL-2 and Ki 67 was studied on all 60 cases and the observations noted down to be further statistically analyzed.
RESULTS:
Analysis revealed significant p value for both Bcl 2 and Ki 67. BCL-2 is an antiapoptotic marker showing positivity in typical hyperplasia cases as compared to atypical or malignant lesions. Ki 67 is a proliferative marker showing increase in its expression in typical to atypical endometrial hyperplastic lesions to malignant lesions.
CONCLUSION:
BCL-2 and Ki 67 can be used as a marker to assess the endometrial hyperplastic progression towards atypia/malignancy.
KEYWORDS:
Antiapoptotic marker, Endometrium, Hyperplasia, Proliferative marker
Downloads
References
2. Paleari, L. (2023). New Strategies for Endometrial Cancer Detection and Management. International Journal of Molecular Sciences, 24(7), 6462.
3. Endometrial Cancer. (2022, May 4). Kauvery Hospital | Patient Newsletters | a Monthly Newsletter From Your Partners in Good Health. Retrieved June 24, 2024, from https://www.kauveryhospital.com/ima-journal/ima-journal-april-2022/endometrial-cancer/
4. Maheshwari, A., Kumar, N., & Mahantshetty, U. (2016). Gynecological cancers: a summary of published Indian data. South Asian journal of cancer, 5(03), 112-120.
5. Byun, J. M., Jeong, D. H., Kim, Y. N., Cho, E. B., Cha, J. E., Sung, M. S., ... & Kim, K. T. (2015). Endometrial cancer arising from atypical complex hyperplasia: The significance in an endometrial biopsy and a diagnostic challenge. Obstetrics & gynecology science, 58(6), 468.
6. Bhati, S., & Negi, S. R. Manuscript type: original research article STUDY OF EXPRESSION OF BCL-2 AND Ki-67 IN BIOPSY SPECIMENS OF NORMAL ENDOMETRIUM AND OTHER ENDOMETRIAL LESIONS-AN OBSERVATIONAL STUDY.
7. Hutt, S., Tailor, A., Ellis, P., Michael, A., Butler-Manuel, S., & Chatterjee, J. (2019). The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta oncologica, 58(3), 342-352.
8. Steinbakk, A., Gudlaugsson, E., Aasprong, O. G., Skaland, I., Malpica, A., Feng, W., ... & Baak, J. P. (2011). Molecular biomarkers in endometrial hyperplasias predict cancer progression. American journal of obstetrics and gynecology, 204(4), 357-e1.
9. Shalini, P., Suresh, N., & Lilly, S. M. (2021). Expression of BCL-2 and KI-67 in Cyclical Endometrium and in Endometrial Hyperplasia. Journal of Pharmaceutical Research International, 33(21A), 1-11.
10. Hassan, W. A. E. M., Adly, M. A., & Ahmed, A. (2019). Expression of Bc-l2 in precancerous endometrial lesion and endometrial carcinoma. Sohag Medical Journal, 23(1), 44-49.
11. Niemann, T. H., Trgovac, T. L., Mcgaughy, V. R., & Vaccarello, L. (1996). bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecologic oncology, 63(3), 318-322.
12. Abd Ali Al-Humairi, I. (2022). Immunohistochemical study of Ki-67 in hyperplastic and endometrium carcinoma: a comparative study. Archives of Razi Institute, 77(1), 229.
13. Swami, R. M., Lakhe, R., Doshi, P., Karandikar, M. N., Nimbargi, R., & Mani, N. S. Immunohistochemical study of ER, PR, p53 and Ki67 expression in patients with endometrial adenocarcinoma and atypical endometrial hyperplasia.
14. Arjunan, A., Nilavu, J., ThiriveniBalajji, G. S., & Praba, V. (2016). Expression of Bcl-2 and Ki-67 in cyclical endometrium and in endometrial hyperplasia–An analysis. IOSR J Dent Med Sci, 15, 43-9.
15. Risberg, B., Karlsson, K., Abeler, V., Lagrelius, A., Davidson, B., & Karlsson, M. G. (2002). Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. International journal of gynecological pathology, 21(2), 155-160.
16. Laban, M., Ibrahim, E. A. S., Agur, W., & Ahmed, A. M. B. E. (2015). Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis. Journal of microscopy and ultrastructure, 3(1), 19-24.
17. Shevra, C. R., Ghosh, A., & Kumar, M. (2015). Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. Journal of postgraduate medicine, 61(1), 15-20.
Copyright (c) 2024 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
